SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Alexion Pharmaceuticals, Inc. (ALXN)
An SI Board Since October 1997
Posts SubjectMarks Bans Symbol
824 29 0 ALXN
Emcee:  Larry Liebman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
399Thanks Wilder I remember C5 has always been negative to the drug and its prospeIcebrg-12/18/2003
398Ice, Here are a couple Y! posts that discussed the compound. During the time okeokalani'nui-12/18/2003
397XOMA and Millennium Announce Initiation of Phase I Clinical Trial of MLN2222 -- Icebrg-12/18/2003
396Alexion Pharmaceuticals and XOMA Form Collaboration Thursday December 18, 6:30 anigel bates-12/18/2003
395[From the shelf filing. It appears they are resigned to run another phase III stIcebrg-11/26/2003
394Alexion Pharmaceuticals files $150 mln shelf offer Wednesday November 26, 5:29 pIcebrg-11/26/2003
393One competing drug down... WASHINGTON (Dow Jones)--A study of Aventis S.A.'Miljenko Zuanic-11/12/2003
392Jim, I was rhetoric. You observed well failure of the mortality benefit at 4 anMiljenko Zuanic-11/11/2003
391BTW, I'm still long but very very uneasy. After the crappy CC yesterday I&#keokalani'nui-11/11/2003
390Alexion Pharmaceuticals common stock has been granted orphan investment status bkeokalani'nui-11/11/2003
389...cont Patients typically become anemic, suffer significant fatigue, and have Icebrg-11/11/2003
388Eculizumab Could Be Paroxysmal Nocturnal Hemoglobinuria Breakthrough [This is aIcebrg-11/11/2003
387Eculizumab has been granted Orphan Drug Status by the European Commission. ErikIcebrg-11/11/2003
386Miljenko, <<Do you need to be critical all the time?>> I'm norkrw-11/10/2003
385<<I'd guess the probably not-so-prospectively defined secondary endpoiMiljenko Zuanic-11/10/2003
384After listening to the conference call, I still don't get it. The phase IIIIan@SI-11/10/2003
383I'd guess the probably not-so-prospectively defined secondary endpoints of drkrw-11/10/2003
382Now attempting to post remainder of PR... Alexion Announces Results of Phase IIIan@SI-11/10/2003
381part II of press release ... Alexion Announces Results of Phase III PRIMO-CABG Ian@SI-11/10/2003
380Alexion Announces Results of Phase III PRIMO-CABG Trial Presented At the AmericaIan@SI-11/10/2003
379I fail to understand why ALXN finds a prospective endpoint with a p-value of .09Ian@SI-11/10/2003
378Thanks Erik. It was a freakin' cure at last year's ASH! Where's thkeokalani'nui-11/5/2003
377Eculizumab, a C5 Complement-Blocking Antibody, Controls Hemolysis in Paroxysmal Icebrg-11/5/2003
376Monday, November 10, 2003 3:00 p.m. Eastern Ian@SI-11/3/2003
375>>you wouldn't happen to know to whom they might owe milestones/royaltIcebrg-10/28/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News